AGENUS INC — Director's Dealing 2023

May 5, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: MiNK Therapeutics, Inc. (INKT)
CIK: 0001840229
Period of Report: 2023-05-03

Reporting Person: AGENUS INC (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-05-03	Common Stock	P	128689	$1.0789	Acquired	21473374	Direct
2023-05-04	Common Stock	P	21473	$1.2223	Acquired	21494847	Direct
2023-05-05	Common Stock	P	100000	$0.9485	Acquired	21594847	Direct
2023-05-05	Common Stock	P	200	$1.25	Acquired	21595047	Direct

Footnotes

F1: Open market purchases reported on this line occurred at a weighted average price of $1.0789 (range of $0.9144 to $1.20).

F2: Agenus Inc. undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.

F3: Open market purchases reported on this line occurred at a weighted average price of $1.0789 (range of $1.20 to $1.25).

F4: On May 5, 2023, Agenus purchased 100,000 shares of MiNk Therapeutics, Inc. common stock from Garo Armen, Agenus's Chairman and CEO, at the same price he paid to acquire the shares on May 2, 2023. The acquisition price represents a 40% discount to the market price as of today's market close.